La Jolla Pharmaceutical (LJPC) announced Monday morning that its Phase 3 study of LJPC-501 in patients with catecholamine resistant hypotension was highly statistically significant in terms of its primary endpoint. Only 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients.
La Jolla Pharmaceutical gapped up sharply Monday and climbed during the first 45 minutes of trade. The stock was range-bound for the rest of the session and closed up by 15.25 at $35.12 on the highest volume of the year. La Jolla Pharmaceutical soared to a new high for the year.
by RTT Staff Writer
For comments and feedback: [email protected]